Recent CTXR News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2024 09:15:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/25/2024 10:15:08 PM
- Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval • PR Newswire (US) • 11/25/2024 01:03:00 PM
- Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split • PR Newswire (US) • 11/22/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2024 09:15:09 PM
- Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering • PR Newswire (US) • 11/18/2024 09:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/18/2024 01:30:32 PM
- Citius Pharmaceuticals Announces $3 Million Registered Direct Offering • PR Newswire (US) • 11/15/2024 06:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2024 09:30:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 10:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 10:00:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 10:00:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 10:00:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 10:00:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/12/2024 10:00:16 PM
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors • PR Newswire (US) • 11/11/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/27/2024 09:25:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 09:26:01 PM
- Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/05/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:15:10 PM
- Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology • PR Newswire (US) • 09/05/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:01:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:35:55 PM
Avant Technologies' Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy • AVAI • Dec 4, 2024 8:00 AM
North Bay Resources Commences Fran Gold Winter Ore Shipment to Bishop Gold Mill, California • NBRI • Dec 2, 2024 9:07 AM
VAYK Reached Agreement on Terms to Acquire $1 Million Company for Disruptive Airbnb Strategy • VAYK • Dec 2, 2024 9:00 AM
ILUS Announces Completion of QIND Acquisition by Fusion Fuel (NASDAQ: HTOO) • ILUS • Nov 27, 2024 12:35 PM
Cannabix Technologies Receives Positive Testing Certification for Breath Logix Autonomous Alcohol Breathalyzer • BLO • Nov 26, 2024 8:48 AM
BioQuest, Inc. and BotMakers Expand AI Marketing Services with SpeedLeads XL and MarketScope XL. Bioquest Corp. and BotMakers, Inc. are Partnered to Expand AI Marketing Services with SpeedLead XL and MarketScope XL • BQST • Nov 26, 2024 8:00 AM